Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cukras, Catherine | - |
dc.contributor.author | Wiley, Henry E. | - |
dc.contributor.author | Jeffrey, Brett G. | - |
dc.contributor.author | Sen, H. Nida | - |
dc.contributor.author | Turriff, Amy | - |
dc.contributor.author | Zeng, Yong | - |
dc.contributor.author | Vijayasarathy, Camasamudram | - |
dc.contributor.author | Marangoni, Dario | - |
dc.contributor.author | Ziccardi, Lucia | - |
dc.contributor.author | Kjellstrom, Sten | - |
dc.contributor.author | Park, Tae Kwon | - |
dc.contributor.author | Hiriyanna, Suja | - |
dc.contributor.author | Wright, J. Fraser | - |
dc.contributor.author | Colosi, Peter | - |
dc.contributor.author | Wu, Zhijian | - |
dc.contributor.author | Bush, Ronald A. | - |
dc.contributor.author | Wei, Lisa L. | - |
dc.contributor.author | Sieving, Paul A. | - |
dc.date.accessioned | 2021-08-11T11:43:47Z | - |
dc.date.available | 2021-08-11T11:43:47Z | - |
dc.date.issued | 2018-09-05 | - |
dc.identifier.issn | 1525-0016 | - |
dc.identifier.issn | 1525-0024 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/5637 | - |
dc.description.abstract | This study evaluated the safety and tolerability of ocular RS1 adeno-associated virus (AAV8-RS1) gene augmentation therapy to the retina of participants with X-linked retinoschisis (XLRS). XLRS is amonogenic trait affecting only males, caused bymutations in the RS1 gene. Retinoschisin protein is secreted principally in the outer retina, and its absence results in retinal cavities, synaptic dysfunction, reduced visual acuity, and susceptibility to retinal detachment. This phase I/IIa single-center, prospective, open-label, three-dose-escalation clinical trial administered vector to nine participants with pathogenic RS1 mutations. The eye of each participant withworse acuity (<= 63 letters; Snellen 20/63) received the AAV8-RS1 gene vector by intravitreal injection. Three participants were assigned to each of three dosage groups: 1e9 vector genomes (vg)/eye, 1e10 vg/eye, and 1e11 vg/eye. The investigational product was generally well tolerated in all but one individual. Ocular events included dose-related inflammation that resolved with topical and oral corticosteroids. Systemic antibodies againstAAV8 increased in a dose-related fashion, but no antibodies against RS1 were observed. Retinal cavities closed transiently in one participant. Additional doses and immunosuppressive regimens are being explored to pursue evidence of safety and efficacy (ClinicalTrials.gov: NCT02317887). | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Nature Publishing Group | - |
dc.title | Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.ymthe.2018.05.025 | - |
dc.identifier.scopusid | 2-s2.0-85049454038 | - |
dc.identifier.wosid | 000447756800019 | - |
dc.identifier.bibliographicCitation | Molecular Therapy, v.26, no.9, pp 2282 - 2294 | - |
dc.citation.title | Molecular Therapy | - |
dc.citation.volume | 26 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 2282 | - |
dc.citation.endPage | 2294 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | TEST-RETEST VARIABILITY | - |
dc.subject.keywordPlus | NEUTRALIZING ANTIBODIES | - |
dc.subject.keywordPlus | MACULAR DEGENERATION | - |
dc.subject.keywordPlus | LIVER TRANSDUCTION | - |
dc.subject.keywordPlus | AAV VECTORS | - |
dc.subject.keywordPlus | MOUSE MODEL | - |
dc.subject.keywordPlus | MICROPERIMETRY | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordAuthor | AAV vector | - |
dc.subject.keywordAuthor | X-linked retinoschisis | - |
dc.subject.keywordAuthor | clinical trial | - |
dc.subject.keywordAuthor | gene therapy | - |
dc.subject.keywordAuthor | ocular disease | - |
dc.subject.keywordAuthor | retinal disease | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.